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Objective: The International Association for the Study of Lung Cancer (IASLC) proposed a revision to the Union
Internationale Contre le Cancer (UICC-6) staging system for non–small cell lung cancer. The goal of our study
was to compare these systems in patients undergoing surgery for non–small cell lung cancer to determine whether
one system is superior in staging operable disease.
Methods: Pathologic stages in 1154 patients undergoing complete resection over a 9-year period were analyzed.
Patients were assigned a stage based on both IASLC and UICC-6 systems. We tested for statistically meaningful
differences between the two staging systems using the Wilcoxon signed rank test and the permutation test.
Results: The IASLC system is more effective than the UICC-6 system at ordering and differentiating patients
(P ¼ .009). Application of the IASLC system resulted in 202 (17.5%) patients being reassigned to a different
stage (P¼ .012), with the most common shifts occurring from IB to IIA and IIIB to IIIA. The 5-year and median
survivals of the IASLC IIIA patients including those shifted from the UICC-6 IIIB were 37% and 35 months,
respectively. Reclassifying UICC-6 IIIB to IASLC IIIA did not reduce survival for the newly characterized
IIIA cohort.
Conclusion: Our data confirm that the proposed IASLC staging system is more effective at differentiating stage
than the UICC-6 system. Reclassifying patients from UICC-6 IIIB to IASLC IIIA will shift some patients from
a stage previously considered unresectable to a stage frequently offered surgical resection. Further study and val-
idation of the IASLC system are warranted.Supplemental material is available online.
Despite the overall poor prognosis of patients with lung can-
cer, there are subsets of patients who benefit from treat-
ment.1-4 Effective staging systems stratify patient survival
and can be used to assess outcome of defined patient sub-
groups after treatment. The sixth edition of the Union Inter-
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doi:10.1016/j.jtcvs.2009.01.033412 The Journal of Thoracic and Cardiovascular Sunationale Contre le Cancer (UICC-6) and the American
Joint Committee on Cancer (AJCC) has served as the current
tumor, node, metastases (TNM) staging system for non–
small cell lung cancer (NSCLC) since 2002.5 The UICC-6
system is derived from the 1997 staging system proposed
by Mountain.6 This staging system was based on 5319 pa-
tients treated for primary lung cancer at The University of
Texas—M. D. Anderson Cancer Center (UTMDACC)
(4351 patients) from 1975 to 1988 or by the National Cancer
Institute Cooperative Lung Cancer Study Group (968
patients) from 1977 to 1982. This represents primarily
a single-institution experience from a single country. The
current staging system has considerable intrastage heteroge-
neity with groups within a stage varying widely in prognosis.
In 1998 the International Association for the Study of
Lung Cancer (IASLC) staging project was initiated to de-
velop the next revision of the current UICC-6 system.7-11
The proposed revision represents data collected from
100,869 patients from Europe, Australia, Asia, and North
America. The data were analyzed by Cancer Research
and Biostatistics and the IASLC International Staging
Committee. The revised system proposes changes to the
T and M classifications (Table 1) and overall stage group-
ings (Table 2). The revised TNM staging has been submit-
ted for approval to the UICC. The IASLC system has yet
to be independently evaluated.rgery c August 2009
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AJCC ¼ American Joint Committee on
Cancer
IASLC ¼ International Association for the
Study of Lung Cancer
NSCLC ¼ non–small cell lung cancer
TNM ¼ tumor, node, metastasis
UICC ¼ Union Internationale
Contre le Cancer
UTMDACC ¼ University of Texas M. D.
Anderson Cancer Center
The goal of our study was to apply the proposed changes to
the current UICC-6 staging system to a cancer center popu-
lation undergoing surgery for NSCLC and to directly com-
pare the proposed IASLC and UICC-6 staging systems
with respect to discrimination, monotonicity and intrastage
heterogeneity.
PATIENTS AND METHODS
Population
This study analyzed data from a prospectively collected database of 1154
patients who underwent an R0 surgical resection for NSCLC at UTMDACC
between 1998 and 2006. UTMDACC was a contributor of patient data for
the IASLC study. Less than 5% of the patients in our study were the same
TABLE 1. Comparison of T and M stage of UICC-6 and IASLC staging systems
A. UICC-6 staging system
Tx: Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or
bronchoscopy
T0: No evidence of primary tumor
Tis: Carcinoma in situ
T1: Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without evidence of invasion more proximal than the lobar bronchus
T2: Tumor more than 3 cm in diameter; or tumor with any of the following features:
 Involves main bronchus, 2 cm or more distal to the carina
 Invades visceral pleura
 Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T3: Tumor more than 7 cm or
 Direct invasion any of the following: chest wall (including superior sulcus tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium
 Tumor in the main bronchus less than 2 cm distal to the carina without carinal invasion
 Associated atelectasis or obstructive pneumonitis of the entire lung
T4: Tumor of any size that invades any of the following:
 Mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body or carina
 Separate tumor nodule(s) in the ipsilateral primary lobe
 Malignant pleural effusion
M1: Distant metastases
B. IASLC staging system
Tx: Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or
bronchoscopy
T0: No evidence of primary tumor
Tis: Carcinoma in situ
T1: Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without evidence of invasion more proximal than the lobar bronchus
T1a: Tumor 2 cm or less in greatest dimension
T1b: Tumor more than 2 cm but not more than 3 cm in greatest dimension
T2: Tumor more than 3 cm but not more than 7 cm or tumor with any of the following features:
 Involves main bronchus, 2 cm or more distal to the carina
 Invades visceral pleura
 Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T2a: Tumor more than 3 cm but not more than 5 cm in greatest dimension
T2b: Tumor more than 5 cm but not more than 7 cm in greatest dimension
T3: Tumor more than 7 cm or
 Direct invasion any of the following: chest wall (including superior sulcus tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium
 Tumor in the main bronchus less than 2 cm distal to the carina
 Associated atelectasis or obstructive pneumonitis of the entire lung
 Separate tumor nodule(s) in the same lobe
T4: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body or carina
Separate tumor nodule(s) in a different ipsilateral lobe
M1a: Tumor nodule in contralateral lung, tumor with pleural nodules, malignant effusion
M1b: Distant metastases
UICC, Union Internationale Contre le Cancer; IASLC, International Association for the Study of Lung Cancer.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 2 413
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same, the length of follow-up was different in the two studies. The two pop-
ulations can be treated as two distinct data sets.
Institutional review board approval was obtained for this study, and in-
formed consent was obtained from each participant.
Patients were excluded from analysis if histologic type was small cell
carcinoma, neuroendocrine carcinoma, or predominantly bronchoalveolar
carcinoma. Chemotherapy or radiation therapy administration did not ex-
clude patients from analysis. A histologic classification of adenocarcinoma
with bronchoalveolar features was included in the analysis. Pathologic stag-
ing of resected specimens was based on the application of the UICC-6 TNM
staging system. Nodal (N) classification for each patient was determined ei-
ther by systematic lymph node dissection or by lymph node sampling. Each
specimen was then reassigned a surgical TNM classification and overall
stage on the basis of the IASLC system.
Data on pathologic TNM classification, overall stage, and outcome for
patients treated at UTMDACC were collected prospectively using Inter-
net-based data collection entered by the health provider at the point of
care. The data are subjected to periodic reviews for quality control.
Statistical Analyses
We tested for statistically meaningful differences between the UICC-6
and IASLC staging systems with respect to stage assignment using a Wil-
coxon signed rank test. Statistical analysis was performed with SPSS soft-
ware (SPSS, Inc, Chicago, Ill).
Survival probabilities were assessed by the Kaplan–Meier method calcu-
lated from the date of surgery until death or most recent follow-up. Operative
mortality was excluded from survival analysis to allow for assessment of
long-term rather than short-term mortality. Each patient was assigned a T clas-
sification and overall stage grouping on the basis of both UICC-6 and IASLC
staging systems (Tables 1 and 2). The prognostic significance of overall stage
using both the UICC-6 and IASLC systems was determined by univariate anal-
ysis. The effectiveness of each staging system was evaluated statistically by
a log–rank trend test. In addition, we also assessed whether one staging system
is more effective than the other via a permutation test in which we construct
TABLE 2. Comparison of TNM stage groupings of IASLC versus
UICC-6 staging systems
Stage UICC-6 IASLC
Stage IA T1 N0 M0 T1a N0 M0
T1b N0 M0
Stage IB T2 N0 M0 T2a N0 M0
Stage IIA T1 N1 M0 T1a N1 M0
T1b N1 M0
T2a N1 M0
T2b N0 M0
Stage IIB T2 N1 M0 T2b N1 M0
T3 N0 M0 T3 N0 M0
Stage IIIA T3 N1 M0 T1a N2 M0
T1-3 N2 M0 T1b N2 M0
T2a N2 M0
T2b N2 M0
T3 N1 M0
T3 N2 M0
T4 N0 M0
T4 N1 M0
Stage IIIB T4, Any N, M0 T4 N2 M0
Any T, N3 M0 Any T, N3, M0
Stage IV Any T, Any N, M1 Any T, Any N, M1 a/b
UICC, Union Internationale Contre le Cancer; IASLC, International Association for
the Study of Lung Cancer.414 The Journal of Thoracic and Cardiovascular Sudifferences in log–rank trend test statistics under random rearrangements
(ie, permutations) of the original labels assigned to the observed data. By
repetition of this process many times (eg, 10,000 times), a null distribution
is created and used to assess the difference between the log–rank trend statistic
under the original labels and the randomly permuted labels.12 Please see the
included appendix for complete description of the statistical analysis.
RESULTS
The population studied included all patients undergoing
curative resection for NSCLC at UTMDACC between
1998 and 2006. The demographics of the study group are
shown in Table 3. Each patient was assigned a pathologic
T classification and overall stage on the basis of both the
UICC-6 and IASLC staging systems. In 952 patients, appli-
cation of the IASLC staging system resulted in no change
from the UICC-6 assigned stage grouping. However, 202
(17.5%) patients were assigned a different stage grouping
when the IASLC staging system was applied to their patho-
logic stage (Wilcoxon signed rank test; P ¼ .012). Of these
202 patients with a change in stage grouping, 73 (36.2%)
patients were upstaged and 129 (63.8%) patients were
downstaged by application of the IASLC staging system
(Figure 1). Patients assigned a higher stage by the IASLC
staging system included patients shifted from UICC-6 IB
to IASLC IIA (n ¼ 44, 60.2%) and IASLC IIB (n ¼ 19,
26%) or UICC-6 IIB to IASLC IIIA (n ¼ 10, 13.7%). Of
the 73 patients who were assigned a higher stage by IASLC,
none was assigned a stage that would preclude surgical re-
section. Application of the IASLC system resulted in down-
staging patients from UICC-6 stages IIB, IIIB, and IV.
Sixty-seven (53.2%) patients classified as being in UICC-
6 IIB were downstaged to IASLC stage IIA. One hundred
four (9%) patients were staged by the UICC-6 as having ad-
vanced locoregional disease precluding surgical resection.
Of these 104 patients with stage IIIB or IV disease, 59
(56%) were restaged by the IASLC system as having poten-
tially respectable disease. Of these, 59 patients in UICC-6
IIIB were downstaged with 51 (40.4%) patients shifted to
TABLE 3. Patient characteristics
Age, y (median, range) 66 (32–90)
Sex (N,%)
Male 607 (52.6)
Female 547 (47.4)
Histology
Adenocarcinoma 658 (57%)
Squamous cell 388 (33.6%)
NSCLC (NOS) 62 (5.4%)
Large cell 24 (2.1%)
Adenosquamous 22 (1.9%)
Procedure
Lobectomy/bilobectomy 947 (82.1%)
Pneumonectomy 94 (8.1%)
Wedge resection 65 (5.6%)
Segmentectomy 48 (4.2%)
NSCLC, Non–small cell lung cancer; NOS, not otherwise specified.rgery c August 2009
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FIGURE 2. Shifting of stage after application of IASLC system. IASLC, International Association for the Study of Lung Cancer.IASLC stage IIIA and 8 (6.3%) patients to IASLC stage IIB.
Three patients were downstaged from stage IV to IIIA (n ¼
2) and IIIB (n ¼ 1). The 5-year and median survivals of the
IIIA patients in the IASLC system, including those shifted
from UICC-6 IIIB, were 37% and 35 months, respectively.
Shifting of patients from UICC stage IIIB, usually consid-
ered unresectable, to IASLC stage IIIA, in which patients
are frequently offered surgical resection, did not result in
a decrease in median or overall survival for IASLC stage
IIIA patients. The 5-year survival of IASLC stage IIA in-
cluding those shifted from UICC-6 IB was 64.7% (Figure 2).
Statistical Comparison of UICC6 and IASLC
Staging Systems
We assessed each staging system’s ability to discriminate
between lower stage and higher stage patients with respect to
overall survival and monotonicity as assessed by strong in-
verse relationship between stage and overall survival using
a permutation test described in the appendix. The IASLC
staging system is significantly more effective with respect
to discrimination and monotonicity than the UICC-6 system.
Application of the permutation test on patients with operable
disease showed that the IASLC staging system is more effec-
tive that the UICC-6 system at predicting overall survival of
patients with operable disease on the basis of stage (P¼ .009).
DISCUSSION
Our study aim was to apply the IASLC T classification
and overall stage groupings to a population of patients
who underwent complete surgical resection for NSCLC at
UTMDACC between 1998 and 2006. The proposed changes
to the staging system represent a major change that will
result in significant shifts of patients into higher or lower
stages. We asked the question whether application of the
IASLC staging system to a cancer center population repli-
cates the findings of the IASLC International Staging Com-
mittee and whether the new IASLC staging system is anThe Journal of Thoracic and Cardiovascular Surimprovement over the UICC-6 staging system. Our findings
confirmed the ordering of stages reported for the IASLC
staging system. Furthermore, direct comparison of the
IASLC and UICC-6 staging systems using the permutation
test demonstrated that the IASLC system is more effective
at differentiating high, mid, and low stage groupings than
the current UICC-6 system at a high level of statistical sig-
nificance. This increased effectiveness of the IASLC staging
system may help identify those patients at higher risk for re-
currence. The improved stratification of survival and limita-
tion of heterogeneity among patients within a stage may
have important implications with regard to clinical research
and adjuvant treatment decisions.
Our data also demonstrate a significant shifting of patients
between stages when the IASLC system was applied to their
pathologic stage. Of the 1154 patients in the study, 202
(17.5%) changed stage when the IASLC system was ap-
plied. One hundred four (9%) patients were staged by the
UICC-6 as having advanced locoregional disease precluding
surgical resection. Of these 104 patients with stage IIIB or
IV disease, 59 (56%) were restaged by the IASLC system
as having potentially resectable disease. Of the 73 patients
who were assigned a higher stage by IASLC, none was as-
signed a stage that would preclude resection.
There are several limitations to this analysis. The study
was based on a single-institution experience with a relatively
small number of patients. The data were entered into a data-
base prospectively but the patients were not entered into this
study on a protocol. The type of surgical resection and extent
of nodal dissection were left to the discretion of the operating
surgeon. Also, there was no centralized pathologic review,
and each pathologic specimen was evaluated on a case-
by-case basis. The strength of the study lies in the prospective
data collection, uniformity of the staging procedures for this
patient population, and the independent evaluation by our
statistician using a novel application of the permutation test
to evaluate the two staging systems at ordering and differen-
tiating patients between stages.gery c August 2009
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adoption of the IASLC staging system.
In the current UICC-6 system, T4 lesions are staged as
IIIB regardless of lymph node status and are considered
unresectable except in special circumstances. In this study,
shifting of stage with application of the IASLC may poten-
tially alter the management of 134 (11.6%) patients. Sixty-
three of these patients were upstaged from a stage where
surgery alone is the recommended treatment to a stage where
adjvant chemotherapy may be considered.13-15 Additionally,
10 patients were upstaged to a stage where neoadjuvant che-
motherapy is frequently offered (stage II to IIIA). The role of
adjuvant and neoadjuvant chemotherapy in these patient
populations may need to be re-evaluated. The IASLC system
T4 lesions would be considered as IIIA or IIIB and the des-
ignation is based on the presence of absence of mediastinal
nodal metastases. Satellite nodules in the ipsilateral primary
lobe are considered unresectable T4 (stage IIIB) disease by
UICC-6 criteria but T3 (stage IIB or IIIA) and potentially
resectable by IASLC. Additionally, a satellite nodule in
the ipsilateral lung but outside the primary lobe is unresect-
able M1 (stage IV) in the UICC-6 system and potentially re-
sectable T4 (stage IIIA or IIIB) by IASLC. The optimal
treatment strategy for these stages needs to be re-evaluated.
Further study and validation of IASLC staging system and
its effects on patient care are warranted.
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Discussion
Dr Bryan Fitch Meyers (St. Louis, Mo). I congratulate Dr Kas-
sis on his presentation. Because there were not any photographs of
aortas or mitral valves, I am going to use some of my time to under-
score some of his findings and elaborate a little bit, then follow up
with two short questions.
First of all, the old system was created using 5000 patients, 90%
of them from a single center, M. D. Anderson, where Dr Kassis is
working right now. The new system was created using morethan
100,000 patients collected worldwide, and it really is an interna-
tional effort to represent uniform staging for patients with lung
cancer. Twenty-eight thousand of those patients actually had
a thoracotomy. This major revision has expanded the ability to
make clear statements about staging.
If we assume that these proposed changes are meaningful and
important changes based on 28,000 operated patients, then what
conclusions would be drawn on the basis of the results of a confir-
matory study like this? First, we would either be reassured or raise
some doubt that the M. D. Anderson method of selecting patients
and treating patients is consistent with those done in the rest of
the world. If we assume that the M. D. Anderson system is repre-
sentative of North America or American techniques, if these results
were discrepant with the findings of the international group, we
would wonder whether North America or America is distinct
from other groups. Fortunately, your results are reassuring in that
they confirm the recommendations by the international group.
It turns out that the findings that interest us most in a staging sys-
tem are three things. What we want to see when one makes a change
in a staging system, particularly a long awaited change like this, is
that patients do shift from one stage to another. Dr Kassis has men-
tioned that 17% of the patients were shifted from one stage to an-
other, and whether you use a P value or not, that is a substantial
and clinically important change in the way that patients were as-
signed a stage. That number in itself tells us this was a meaningful
change. The other aspects that are important are the distinctiveness
of the stage groups and the heterogeneity within each stage group.
If you look at Dr Kassis’ slide of the old system, with the stage
IIA curve crossing over the IIB and then crossing over the IB, there
is deficiency in the distinctiveness of the curves. However, if you
move to the next slide where they applied the new staging system
to their own data, you see that that distinctiveness has been im-
proved with the new system. So, again, his presentation shows
the superiority of the new system.Cardiovascular Surgery c Volume 138, Number 2 417
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pertains to the problem of heterogeneity within each stage group.
Is there a way that you could add to these results that reassures
us that the patients who moved were moved from a group where
they were less representative to a group that they now are more rep-
resentative and homogeneous in their new stage group?
Dr Kassis. We did not definitively look at heterogeneity be-
tween stages, although that is a very good question and something
that we could certainly evaluate at a future time. What we did do,
though, is attempt to look at Kaplan–Meier curves in terms of strat-
ifying these patients based on their ability to differentiate patients
on the basis of stage. We took it one step further to try and do a sta-
tistical assessment of these patients by using a model called the per-
mutation test to help quantify the differences that we see based on
the Kaplan–Meier curve. However, your question regarding hetero-
geneity is something that we need to look at in the future.
DrMeyers. The other question I had for you is that when we do
a model, either a predictive or a descriptive model, and we want to
validate it, we often use cases that were not used to create the
model, and this was not mentioned in your presentation or the pa-
per. Did the M. D. Anderson patients who were presented here play
a role in the 28,000 operated patients who were used to create this
new model? What are your thoughts on the impact of your answer
on the importance of these results?
Dr Kassis. Less than 10% of our patient population of the 1154
patients was analyzed by the IASLC system, and the length of fol-
low-up was such that in our estimation they are two completely
separate data sets.
Dr Frank C. Detterbeck (New Haven, Conn). I just have
a comment. I think that we need to be careful about what we418 The Journal of Thoracic and Cardiovascular Suare trying to get from this. There are many purposes to a staging
system. One is to have a nomenclature so that when one person is
talking about certain patients in one study and another person is
talking about them in another institution, the same group of pa-
tients are being discussed. Another is to determine prognosis,
and that is clearly what was chosen as the primary goal in the
IASLC staging project. And clearly it meets that goal. I think
a third one, which is to select appropriate treatment for patients,
is a bit of a slippery slope. That is not what the IASLC staging
project was designed to do and it is not what staging systems
are designed to do. Now, we use the language to help us talk
about it, but it is really clinical trials that define what the appro-
priate treatment is for patients. We cannot just identify a stage (eg,
stage II) and base treatment merely on that. We have to look at
which patients we are talking about and what the clinical trials
have shown us that we should be doing.
I think that you are taking the stage classification system to a dif-
ferent realm here than what it was intended to do, and I am not sure
that that is really appropriate.
Dr Kassis. Thank you for your comments. I do agree with you. I
do not think that we should be altering patient management on the
basis of the stage shifting that we have demonstrated here. What I
am trying to demonstrate is that the shifting of patients may lead to
further studies so that we can better assess and better determine
what to do with these patients with a satellite nodule in the ipsilat-
eral lobe that was formerly T4 in stage IIIB disease. In the current
system, if they are N0, they are going to be stage IIB; if they are N1,
they are going to be stage IIIA. I think we need further studies to
evaluate how we are going to manage these patients now that are
assigned different stage groupings.rgery c August 2009
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The main purpose of this section is to provide a formal sta-
tistical test for comparing two staging systems (the standard
AJCC nodal staging system for esophageal cancer and
a modified AJCC nodal staging system) with respect to as-
sessing the discrimination between lower and higher stage
disease and assessing the monotonic relationship between
stage and survival. Before we can compare these two staging
systems, we must first define what makes a staging system
effective. We also must define how to quantify this effective-
ness, and last, we must have a way of statistically comparing
the effectiveness of the two staging systems.
The characteristic that defines the effectiveness of any
staging system is its ability to differentiate, within a given
disease, between patients with low-stage patients (those pa-
tients who survive a long time), mid-stage patients (patients
who survive a moderate amount of time, and high-stage pa-
tients (patients who survive a relatively short amount of
time). Thus an effective staging system is characterized by
(1) the ability to discriminate between lower and higher
stage patients with respect to survival and (2) a monotone
decreasing relationship between stage and survival; this
monotone relationship is quantified graphically by Ka-
plan–Meier curves. Moreover, this type of monotone rela-
tionship between stage and survival may be quantified
numerically by a log–rank trend test.A1 This statistic is
used because it characterizes the effectiveness of a staging
system as defined above: the more effective the staging sys-
tem (ie, the stronger the relationship between stage and sur-
vival), the larger the value of the log–rank trend test statistic.
Inasmuch as the log–rank trend test is available and can eas-
ily be calculated,A2 we chose this statistic as a metric for
measuring the strength of the association between stage
and survival.
Once we have quantified the strength of the relationship
between stage and survival of each of the two staging sys-
tems (ie, assessed the effectiveness of each staging system)
using the log–rank trend test statistic, we also need to assess
whether one staging system has a stronger relationship be-
tween stage and survival than the other staging system.
The complicating factor in assessing the difference in effec-
tiveness of the two staging systems is that the same set of
patients are categorized under both systems inducing corre-
lation between the two log–rank trend test statistics. We
address this complicating factor by assessing differences
between staging systems in the strength of the relationship
between stage and survival via a permutation (randomiza-
tion) test. A permutation test is a type of hypothesis test in
which the null distribution is obtained by calculating possi-
ble values of the test statistic under random rearrangements
(ie, permutations) of the original labels assigned to the ob-
served data.A3 By repeating this process many times (eg,
1000 times), we create a null distribution. Creation of
a null distribution in this way only differs from null distribu-The Journal of Thoracic and CaTrend Test Differences
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APPENDIX FIGURE 1. Distribution of differences under the null distri-
bution.
tions derived from statistical theory (eg, standard normal, c2,
F) in how the null distribution is obtained but does not differ
in how they are used or interpreted. An added benefit of us-
ing null distributions derived from permutation tests is that
they can be used in situations in which the null distribution
is difficult to construct analytically (as in this case).
Each of the staging systems under consideration in this anal-
ysis has five staging categories. We call these five categories
stage 1A, stage 1B, stage IIA, stage IIB, and stage IIIA. Under
the null hypothesis for our permutation test, we assume that the
two staging systems are exchangeable. This means that under
the null hypothesis we assume that there is no difference be-
tween the two staging systems with respect to the strength of
each staging system’s relationship between stage and survival.
The alternative hypothesis is that there is difference in the two
staging systems with respect to the strength of the relationship
between stage and survival. To assess these hypotheses, we
construct our test statistic, which is the difference in the two
trend tests calculated under each staging system. For the
observed data, the difference in the two staging system
log–rank test statistics is 12.07 (53.88 for the UICC-6 staging
system and 65.95 for the IASLC staging system). These log–
rank trend tests tell us that both methods show a strong rela-
tionship between stage and survival. However, it appears
that the IASLC staging system is better inasmuch as the ob-
served test statistic is larger for this staging system and larger
test statistics imply stronger evidence that the null hypothesis
(ie, no relationship between stage and survival) should be re-
jected. To formally test whether the IASLC staging system
is indeed statistically better (and assess whether the differences
in test statistics may only be due to chance), we construct our
null distribution to which this observed test statistic will be
compared by performing the following steps:
1. For each patient with 50% probability, we randomly rear-
range (ie, permute) the staging system labels originally as-
signed to that patient. That is, for a given patient the stagerdiovascular Surgery c Volume 138, Number 2 418.e1
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and the stage assignment is now considered to have
been assigned under the modified system and vice versa).
2. Once all patients have been permuted, we calculate the
log–rank trend test statistic for the two staging systems
and record the permuted difference in log–rank trend
tests.
3. We repeat steps 1 and 2 a total of 1000 times.
The null distribution we construct using this method is
given in Appendix Figure 1.
As shown, the differences in the trend statistics under the
null distribution are centered around 0 as one would expect418.e2 The Journal of Thoracic and Cardiovascular Surif there were no difference between staging systems in their
ability to differentiate between low, middle, and high stage pa-
tients. Moreover, the probability of observing a difference in
trend statistics is rare inasmuch as 12.07 is only 0.009 under
the null hypothesis of no difference in the two staging systems.
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